Beatrix Elsberger

Beatrix Elsberger

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in European Journal of Cancer
Verified
Journal Article
Open access
STSarah Shuk-Kay Tang
Sarah Shuk-Kay Tang
SKSarantos Kaptanis
Sarantos Kaptanis
JHJames B. Haddow
James B. Haddow
JMJo Mondani
Jo Mondani
BEBeatrix Elsberger
Beatrix Elsberger
YMYazan Masannat
Yazan Masannat
There is variation in margin policy for breast conserving therapy (BCT) in the UK and Ireland. In response to the Society of Surgical Oncology and American Society for Radiation Oncology (SSO-ASTRO) margin consensus ('no ink on tumour' for invasive and 2 mm for ductal carcinoma in situ [DCIS]) and the Association of Breast Surgery (ABS) consensus (1 mm for invasive and DCIS), we report on current margin practice and unit infrastructure in the UK and Ireland and describe how these factors impact on re-excision rates. A trainee collaborative-led multicentre prospective study was conducted in the UK and Ireland between 1st February and 31st May 2016. Data were collected on consecutive BCT patients and on local infrastructure and policies. A total of 79 sites participated in the data collection (75% screening units; average 372 cancers annually, range 70-900). For DCIS, 53.2% of units accept 1 mm and 38% accept 2-mm margins. For invasive disease 77.2% accept 1 mm and 13.9% accept 'no ink on tumour'. A total of 2858 patients underwent BCT with a mean re-excision rate of 17.2% across units (range 0-41%). The re-excision rate would be reduced to 15% if all units applied SSO-ASTRO guidelines and to 14.8% if all units followed ABS guidelines. Of those who required re-operation, 65% had disease present at margin. There continues to be large variation in margin policy and re-excision rates across units. Altering margin policies to follow either SSO-ASTRO or ABS guidelines would result in a modest reduction in the national re-excision rate. Most re-excisions are for involved margins rather than close margins.

1 March 2014 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
BEBeatrix Elsberger
Beatrix Elsberger

30 January 2023 in The Lancet Oncology
Verified
Journal Article
Closed access
SCSubarnarekha Chatterji
Subarnarekha Chatterji
EKEmma Krzoska
Emma Krzoska
CTChristopher W Thoroughgood
Christopher W Thoroughgood
JSJohn Saganty
John Saganty
PLPeng Liu
Peng Liu
VSValerie Speirs
Valerie Speirs

1 February 2014 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
BEBeatrix Elsberger
Beatrix Elsberger
ARA. Romsauerova
A. Romsauerova
SVS. Vinnicombe
S. Vinnicombe
PWP. Whelehan
P. Whelehan
DBD.C. Brown
D.C. Brown
AEA. Evans
A. Evans

4 April 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
JMJenna L. Morgan
Jenna L. Morgan
VCVinton Cheng
Vinton Cheng
PBPeter A. Barry
Peter A. Barry
ECEllen Copson
Ellen Copson
RCRamsey I Cutress
Ramsey I Cutress
BKBaek Kim
Baek Kim
Evidence based guidelines for the optimal management of breast cancer locoregional recurrence (LRR) are limited, with potential for variation in clinical practice. This national practice questionnaire (NPQ) was designed to establish the current practice of UK breast multidisciplinary teams (MDTs) regarding LRR management. UK breast units were invited to take part in the MARECA study MDT NPQ. Scenario-based questions were used to elicit preference in pre-operative staging investigations, surgical management, and adjuvant therapy. 822 MDT members across 42 breast units (out of 144; 29%) participated in the NPQ (February-August 2021). Most units (95%) routinely performed staging CT scan, but bone scan was selectively performed (31%). For patients previously treated with breast conserving surgery (BCS) and radiotherapy, few units (7%) always/usually offered repeat BCS. However, in the absence of radiotherapy, most units (90%) always/usually offered repeat BCS. For patients presenting with isolated local recurrence following previous BCS and SLNB (sentinel lymph node biopsy), most units (95%) advocated repeat SLNB. Where SLNs could not be identified, 86% proceeded to a four-node axillary sampling procedure. For ER positive, HER2 negative, node negative local recurrence, 10% of units always/usually offered chemotherapy. For ER positive, HER2 negative, node positive local recurrence, this recommendation increased to 64%. For triple negative breast cancer local recurrence, 90% of units always/usually offered chemotherapy. This survey has highlighted where consistencies and variations exist in the multidisciplinary management of breast cancer LRR. However, further research is required to determine how these management patterns influence patient outcomes, which will further refine optimal treatment pathways.

28 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DMDylan Peter McClurg
Dylan Peter McClurg
GUGordan Urquhart
Gordan Urquhart
TMTrevor McGoldrick
Trevor McGoldrick
SCSubarnarekha Chatterji
Subarnarekha Chatterji
ZMZosia Miedzybrodzka
Zosia Miedzybrodzka
BEBeatrix Elsberger
Beatrix Elsberger
Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all breast cancers and male malignancies. Despite recognised clinico-pathological and molecular differences to female breast cancer (FBC), the clinical management of MBC follows established FBC treatment strategies. Loss of function mutations in the DNA damage response genes BRCA1 and BRCA2, have been strongly implicated in the pathogenesis of MBC. While there have been extensive clinical advancements in other BRCA-related malignancies, including FBC, improvements in MBC remain stagnant. Here we present a review that highlights the lack of treatment evidence for BRCA-related MBC and the required national and global collaborative effort to address this unmet need. In doing so, we summarise the transformative clinical advancements with poly(ADP-ribose) polymerase (PARP) inhibitors in other BRCA-related cancers namely, FBC and prostate cancer.